10-Q: Traws Pharma Reports Q3 2024 Results, Cites Going Concern Uncertainty Amidst Strategic Shift

Traws Pharma's Q3 2024 results reveal a significant net loss driven by a large in-process R&D expense, alongside ongoing concerns about the company's ability to continue as a going concern.

Summary

• Traws Pharma reported a net loss of $136.6 million for the nine months ended September 30, 2024, compared to a $14.8 million loss in the same period of 2023.
• The company's accumulated deficit reached $619.2 million as of September 30, 2024.
• A major factor in the increased loss was a $117.5 million non-cash expense for acquired in-process research and development (IPR&D) related to the acquisition of Trawsfynydd Therapeutics.
• Operating expenses totaled $137.3 million for the nine months ended September 30, 2024, which included $117.5 million in IPR&D, $11 million in research and development, and $8.8 million in general and administrative costs.
• The company's cash and cash equivalents stood at $5.4 million as of September 30, 2024.
• Traws Pharma believes its current cash will fund operations into the first quarter of 2025, but it has expressed substantial doubt about its ability to continue as a going concern beyond that point.
• The company is exploring various funding options, including equity financing and strategic alliances, to address its liquidity concerns.
• Revenue remained consistent at $170,000 for both the nine months ended September 30, 2024 and 2023, primarily from a licensing agreement with SymBio.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a significant net loss, low cash reserves, and a 'going concern' warning. While there are some positive developments in clinical trials, the overall sentiment is negative due to the financial instability and uncertainty.

Positives

• Traws Pharma successfully completed a private placement in April 2024, raising approximately $14 million.
• The company regained compliance with Nasdaq's minimum bid price requirement in October 2024.
• The company is advancing four clinical programs, including two antiviral and two oncology programs.
• Topline data from the Phase 1 study of TRX100 showed good overall tolerability and a pharmacokinetic profile that appears to support the potential use of TRX100 as a one-time treatment for influenza.
• Topline data from the Phase 1 study of TRX01 showed no treatment related adverse events reported up to the highest dose and that once-daily administration of TRX01 for 10 consecutive days maintained plasma drug levels within the predicted therapeutic window for 12 days.
• The recommended Phase 2 dose (RP2D) of narazaciclib in combination with letrozole in low grade endometrioid endometrial cancers has been identified.

Negatives

• Traws Pharma reported a significant net loss of $136.6 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $619.2 million as of September 30, 2024.
• The company has expressed substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.
• Traws Pharma is not in compliance with the minimum stockholders equity requirement for continued listing on Nasdaq.
• The company incurred a $117.5 million non-cash expense for acquired in-process research and development (IPR&D) due to the Trawsfynydd Therapeutics acquisition.
• Operating expenses increased significantly to $137.3 million for the nine months ended September 30, 2024.
• Other income decreased due to lower interest income from reduced cash balances.

Risks

• The company has expressed substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.
• Traws Pharma is not in compliance with the minimum stockholders equity requirement for continued listing on Nasdaq.
• The company faces risks related to the development, regulatory approval, and commercialization of its product candidates.
• There are risks associated with integrating the businesses of Onconova and Trawsfynydd.
• The company may not be able to obtain additional funding on acceptable terms or at all.
• The company's future success depends on its ability to obtain additional funding.
• The company's clinical trials may not be successful, and regulatory approvals may not be granted.
• The company may face competition from other pharmaceutical companies.
• The company may not be able to protect its intellectual property.
• The company may face third-party disputes and litigation.

Future Outlook

The company anticipates that operating losses will continue for the foreseeable future due to costs related to research, development of its product candidates, strategic alliances, and its administrative organization. The company believes its cash will fund operations into the first quarter of 2025, but it has expressed substantial doubt about its ability to continue as a going concern beyond that point. The company plans to explore various funding options, including equity financings, strategic alliances, and business development.

Management Comments

• Management plans to explore various dilutive and non-dilutive sources of funding, including equity financings, strategic alliances, business development and other sources.
• Management believes that its cash and cash equivalents will be sufficient to fund its ongoing trials and operations into the first quarter of 2025.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Traws Pharma's focus on respiratory viral diseases and cancer aligns with areas of significant unmet medical need, but also faces intense competition and high risk of failure. The company's acquisition of Trawsfynydd Therapeutics and its pipeline of antiviral compounds reflects a strategic shift to diversify its portfolio and address emerging health threats.

Comparison to Industry Standards

• The $117.5 million expense for acquired in-process R&D is a significant non-cash charge, which is not uncommon in the biopharmaceutical industry following acquisitions of early-stage assets.
• The company's cash position of $5.4 million is low for a clinical-stage company, especially one with multiple ongoing programs, and is below the industry average for companies at a similar stage of development.
• The company's need for additional financing is typical for biopharmaceutical companies, but the stated 'going concern' uncertainty is a significant concern and is not typical for companies that have recently raised capital.
• The company's focus on both oncology and virology is a diversification strategy, but it also increases the complexity of the business and the need for capital.
• The company's clinical trial progress is in line with industry standards, but the timelines for Phase 2 studies are dependent on securing additional funding.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any pending material legal proceedings and is not aware of any such proceedings contemplated by governmental authorities.
• Steven M. Fruchtman informed the Board of his intent to resign from his positions of President and Chief Scientific Officer, Oncology and indicated to the Company that Dr. Fruchtman believes his resignation to be for 'good reason' under the terms of his employment agreement and his expectation of compensation commensurate therewith and in connection with a change in control. The Board accepted Dr. Fruchtmans resignation effective immediately but disagrees with the characterization of the events set forth in the letter.

Related Party Transactions

• The company made payments to ChemDiv, Inc. of $5,024,000, which primarily relate to services completed prior the acquisition. Dr. Nikolay Savchuk, COO of the Company, is a stockholder of ChemDiv and a member of its board of directors.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and 'going concern' warning.
• Employees have experienced layoffs and restructuring, which may impact morale and job security.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors may be at risk due to the company's financial difficulties.

Next Steps

• The company plans to complete the Phase 1 trial of TRX100 in Australia.
• The company plans to initiate a Phase 2 study of TRX100 in the first half of 2025.
• The company plans to initiate a Phase 2 study of TRX01 in the first half of 2025.
• The company plans to interact with BARDA and CDC in the USA for potential collaboration and funding for the development of TRX100.
• The company plans to establish additional partnerships for further development of narazaciclib.
• The company is pursuing orphan drug designation for rigosertib for epidermolysis bullosa-associated squamous cell carcinoma with the FDA.
• The company will continue to explore various funding options to address its liquidity concerns.

Key Dates

Keywords

Traws Pharma, biopharmaceutical, clinical stage, respiratory viral diseases, cancer, Tivoxavir marboxil, Ratutrelvir, Narazaciclib, Rigosertib, COVID-19, influenza, endometrial cancer, reverse stock split, Nasdaq, going concern, clinical trials, research and development, asset acquisition, stock compensation, private placement